Physician profile
Melanie L Aya-Ay
NPI 1497943591
$282,704.28
in general payments reported to CMS, 2019-2025
18 companies · $123K in 2025
The $123K reported for 2025 was more than what 99% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $1,144 · 2021: $719 · 2022: $12K · 2023: $69K · 2024: $76K · 2025: $123K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $191K · Consulting Fee: $44K · Travel and Lodging: $22K · Food and Beverage: $9,400 · Long Term Medical Supply Or Device Loan: $1,553 · Education: $50.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $191,012.50 |
| Consulting Fee | $43,918.41 |
| Travel and Lodging | $22,115.98 |
| Food and Beverage | $9,400.46 |
| Long Term Medical Supply Or Device Loan | $1,553.00 |
| Education | $50.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264,249.76 | 2023-2025 | Botox, Natrelle Saline-Filled Breast Implants, Strattice Reconstructive Tissue Matrix Bps |
| Allergan, INC. | $12,383.46 | 2019-2022 | |
| Integra Lifesciences Corporation | $1,804.64 | 2023-2025 | Durasorb Monofilament Mesh, Integra, Integra Dermal Regeneration Template |
| Mentor Worldwide LLC | $1,634.68 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 2 Breast Tissue Expander |
| Merz North America, INC. | $797.88 | 2020-2022 | |
| Tepha INC | $389.21 | 2020 | |
| Musculoskeletal Transplant Foundation INC. | $355.25 | 2023-2024 | |
| Galderma Laboratories, L.P. | $296.08 | 2021-2024 | |
| Motiva USA, LLC | $181.12 | 2025 | |
| Bard Peripheral Vascular, INC. | $155.21 | 2021 | |
| Davol INC. | $111.81 | 2022 | |
| Baxter Healthcare | $109.35 | 2025 | Tisseel |
| Revance Therapeutics, INC. | $94.80 | 2025 | Daxxify |
| Smith+Nephew, INC. | $53.58 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $30.95 | 2020-2025 | Exparel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sientra, INC. | $20.57 | 2020 | |
| Medtronic USA, INC. | $19.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.12 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Aya-Ay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.